RARE - Ultragenyx Pharmaceutical Inc.

25.06
0.250   0.998%

Share volume: 1,447,708
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$24.81
0.25
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 10%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.20%
1 Month
23.63%
3 Months
10.15%
6 Months
-26.70%
1 Year
-29.21%
2 Year
-42.64%
Key data
Stock price
$25.06
P/E Ratio 
0.00
DAY RANGE
$24.25 - $25.28
EPS 
-$5.83
52 WEEK RANGE
$18.29 - $42.37
52 WEEK CHANGE
-$30.21
MARKET CAP 
2.219 B
YIELD 
N/A
SHARES OUTSTANDING 
96.630 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
1.12
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,703,668
AVERAGE 30 VOLUME 
$2,022,661
Company detail
CEO: Emil D. Kakkis
Region: US
Website: ultragenyx.com
Employees: 1,310
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Ultragenyx Pharmaceutical Inc. focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the. treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia.

Recent news